BR9906799A - Composto, processo de tratamento de uma condição hiperlipidêmica em um mamìfero, composição farmacêutica, e, processo para a preparação de um composto - Google Patents
Composto, processo de tratamento de uma condição hiperlipidêmica em um mamìfero, composição farmacêutica, e, processo para a preparação de um compostoInfo
- Publication number
- BR9906799A BR9906799A BR9906799-4A BR9906799A BR9906799A BR 9906799 A BR9906799 A BR 9906799A BR 9906799 A BR9906799 A BR 9906799A BR 9906799 A BR9906799 A BR 9906799A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- treating
- pharmaceutical composition
- mammal
- preparing
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 241000124008 Mammalia Species 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000055 hyoplipidemic effect Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
"COMPOSTO, PROCESSO DE TRATAMENTO DE UMA CONDIçãO HIPERLIPIDêMICA EM UM MAMìFERO, COMPOSIçãO FARMACêUTICA, E, PROCESSO PARA A PREPARAçãO DE UM COMPOSTO". A invenção refere-se aos novos compostos hipolipidêmicos de fórmula (I), na qual R^ 1^ é H ou metila, e aos seus sais, solvatos ou derivados fisiologicamente funcionais, aos processos e aos novos intermediários para sua preparação, às composições farmacêuticas contendo-os e ao seu uso em medicina, particularmente na profilaxia e no tratamento de condições hiperlipidêmicas e doenças associadas, tal como aterosclerose.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9800428.6A GB9800428D0 (en) | 1998-01-10 | 1998-01-10 | Chemical compounds |
| PCT/EP1999/000021 WO1999035135A1 (en) | 1998-01-10 | 1999-01-07 | Hypolipidemic benzothiazepine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9906799A true BR9906799A (pt) | 2000-10-10 |
Family
ID=10825042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9906799-4A BR9906799A (pt) | 1998-01-10 | 1999-01-07 | Composto, processo de tratamento de uma condição hiperlipidêmica em um mamìfero, composição farmacêutica, e, processo para a preparação de um composto |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US6465451B1 (pt) |
| EP (1) | EP1045840A1 (pt) |
| JP (1) | JP2002500220A (pt) |
| KR (1) | KR20010033988A (pt) |
| CN (1) | CN1292785A (pt) |
| AP (1) | AP2000001860A0 (pt) |
| AR (1) | AR014261A1 (pt) |
| AU (1) | AU2515599A (pt) |
| BR (1) | BR9906799A (pt) |
| CA (1) | CA2317651A1 (pt) |
| CO (1) | CO4820391A1 (pt) |
| EA (1) | EA200000623A1 (pt) |
| GB (1) | GB9800428D0 (pt) |
| HR (1) | HRP20000468A2 (pt) |
| HU (1) | HUP0201343A3 (pt) |
| ID (1) | ID25495A (pt) |
| IL (1) | IL137040A0 (pt) |
| IS (1) | IS5551A (pt) |
| MA (1) | MA26595A1 (pt) |
| NO (1) | NO20003514L (pt) |
| NZ (1) | NZ505453A (pt) |
| PE (1) | PE20000179A1 (pt) |
| PL (1) | PL341672A1 (pt) |
| SK (1) | SK10242000A3 (pt) |
| TR (1) | TR200001816T2 (pt) |
| WO (1) | WO1999035135A1 (pt) |
| ZA (1) | ZA9981B (pt) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6642268B2 (en) | 1994-09-13 | 2003-11-04 | G.D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors |
| KR20010102964A (ko) * | 1998-12-23 | 2001-11-17 | 윌리암스 로저 에이 | 심장혈관 징후를 위한 회장 담즙산 수송 억제인자 및피브린산 유도체의 조합물 |
| DE69908643T2 (de) | 1998-12-23 | 2004-05-13 | G.D. Searle Llc, Chicago | Kombinationen von cholesteryl ester transfer protein inhibitoren und nicotinsäure derivaten für kardiovaskuläre indikationen |
| SE0000772D0 (sv) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | Chemical compounds |
| US20020061888A1 (en) * | 2000-03-10 | 2002-05-23 | Keller Bradley T. | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders |
| US20020183307A1 (en) * | 2000-07-26 | 2002-12-05 | Tremont Samuel J. | Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake |
| SE0003766D0 (sv) * | 2000-10-18 | 2000-10-18 | Astrazeneca Ab | Novel formulation |
| EG26979A (en) * | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
| GB0121337D0 (en) * | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
| GB0121621D0 (en) * | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| GB0121622D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| MY131995A (en) | 2001-09-08 | 2007-09-28 | Astrazeneca Ab | Benzothiazepine and benzothiadiazepine derivatives with illeal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia |
| JP2005521653A (ja) | 2002-01-17 | 2005-07-21 | ファルマシア コーポレイション | 先端ナトリウム同時依存性胆汁酸輸送（ａｓｂｔ）およびタウロコール酸塩取込みの阻害剤としての新規アルキル／アリールヒドロキシまたはケトチエピン化合物 |
| GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
| FR2849024B1 (fr) * | 2002-12-20 | 2007-11-02 | Aventis Pharma Sa | Nouveaux composes chiraux derives d'esters de l'acide hexanoique, procede et intermediaires de preparation, utilisation a la synthese de l'acide 2-(bromomethyl)2-ethyl hexanoique chiral |
| GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
| GB0307918D0 (en) | 2003-04-05 | 2003-05-14 | Astrazeneca Ab | Therapeutic use |
| CN102316872B (zh) | 2008-11-26 | 2016-12-21 | 萨蒂奥根制药公司 | 治疗肥胖症和糖尿病的胆汁酸再循环抑制剂 |
| EP4137137A1 (en) | 2010-05-26 | 2023-02-22 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
| CA2815749C (en) | 2010-11-04 | 2019-12-03 | Albireo Ab | Ibat inhibitors for the treatment of liver diseases |
| SG190433A1 (en) | 2010-11-08 | 2013-06-28 | Albireo Ab | A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder |
| EP2770990A4 (en) | 2011-10-28 | 2015-03-11 | Lumena Pharmaceuticals Inc | Gallic acid refluxing agent for the treatment of hypertension and chronic liver disease |
| PT2771003T (pt) | 2011-10-28 | 2017-07-26 | Lumena Pharmaceuticals Llc | Inibidores da reciclagem de ácidos biliares para tratamento de doenças hepáticas colestáticas pediátricas |
| AU2014228850A1 (en) | 2013-03-15 | 2015-10-29 | Lumena Pharmaceuticals Llc | Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease |
| MX2015013196A (es) | 2013-03-15 | 2016-04-15 | Lumena Pharmaceuticals Inc | Inhibidores de reciclaje de acidos biliares para el tratamiento de la enfermedad de reflujo gastroesofagico y esofago de barrett. |
| JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
| JP6751020B2 (ja) | 2014-06-25 | 2020-09-02 | Ｅａファーマ株式会社 | 固形製剤及びその着色防止又は着色低減方法 |
| EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
| US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| EP3413878B1 (en) | 2016-02-09 | 2021-04-14 | Albireo AB | Oral cholestyramine formulation and use thereof |
| US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| JP6954926B2 (ja) | 2016-02-09 | 2021-10-27 | アルビレオ・アクチボラグ | 経口コレスチラミン製剤及びその使用 |
| US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
| CA3071285A1 (en) | 2017-08-09 | 2019-02-14 | Albireo Ab | Cholestyramine granules, oral cholestyramine formulations and use thereof |
| WO2019032027A1 (en) | 2017-08-09 | 2019-02-14 | Albireo Ab | CHOLESTYRAMINE TABLETS, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE |
| TW202015699A (zh) | 2018-06-05 | 2020-05-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽汁酸調節劑之用途 |
| US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| WO2019245448A1 (en) | 2018-06-20 | 2019-12-26 | Albireo Ab | Crystal modifications of odevixibat |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| MX2021008981A (es) | 2019-02-06 | 2021-09-08 | Albireo Ab | Compuestos de benzotiadiazepina y su uso como moduladores del acido biliar. |
| CN118834175A (zh) | 2019-02-06 | 2024-10-25 | 阿尔比里奥公司 | 苯并硫氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途 |
| US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| WO2020167964A1 (en) | 2019-02-12 | 2020-08-20 | Mirum Pharmaceuticals, Inc. | Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency |
| AR120676A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como ácido biliar |
| TWI877263B (zh) | 2019-12-04 | 2025-03-21 | 瑞典商艾爾比瑞歐公司 | 苯并噻二氮呯化合物及其作為膽酸調節劑之用途 |
| CN114761080B (zh) * | 2019-12-04 | 2024-07-23 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| CA3158175A1 (en) * | 2019-12-04 | 2021-06-10 | Per-Goran Gillberg | Benzothiazepine compounds and their use as bile acid modulators |
| CN114761018B (zh) | 2019-12-04 | 2025-12-02 | 阿尔比里奥公司 | 苯并硫杂二氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| CN114786772B (zh) * | 2019-12-04 | 2024-04-09 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| AR120679A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como moduladores ácido biliar |
| BR112022010505A2 (pt) | 2019-12-04 | 2022-09-06 | Albireo Ab | Compostos de benzotia(di)azepina e seu uso como moduladores do ácido biliar |
| WO2021110884A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| WO2021110887A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| CA3186857A1 (en) | 2020-08-03 | 2022-02-10 | Per-Goran Gillberg | Benzothia(di)azepine compounds and their use as bile acid modulators |
| JP2023549226A (ja) | 2020-11-12 | 2023-11-22 | アルビレオ エービー | 進行性家族性肝内胆汁うっ滞症（ｐｆｉｃ）を処置するためのオデビキシバット |
| WO2022117778A1 (en) * | 2020-12-04 | 2022-06-09 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
| CN119343140A (zh) | 2022-06-09 | 2025-01-21 | 阿尔比里奥公司 | 治疗肝炎 |
| WO2025146508A1 (en) | 2024-01-05 | 2025-07-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| WO2025146507A1 (en) | 2024-01-05 | 2025-07-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0723449A1 (en) | 1993-08-06 | 1996-07-31 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
| ZA956647B (en) | 1994-08-10 | 1997-02-10 | Wellcome Found | Hypolipidaemic compounds. |
| GB9423172D0 (en) * | 1994-11-17 | 1995-01-04 | Wellcom Foundation The Limited | Hypolipidemic benzothiazepines |
-
1998
- 1998-01-10 GB GBGB9800428.6A patent/GB9800428D0/en not_active Ceased
-
1999
- 1999-01-06 ZA ZA9900081A patent/ZA9981B/xx unknown
- 1999-01-06 AR ARP990100035A patent/AR014261A1/es unknown
- 1999-01-06 PE PE1999000007A patent/PE20000179A1/es not_active Application Discontinuation
- 1999-01-07 ID IDW20001337A patent/ID25495A/id unknown
- 1999-01-07 HU HU0201343A patent/HUP0201343A3/hu unknown
- 1999-01-07 US US09/582,907 patent/US6465451B1/en not_active Expired - Fee Related
- 1999-01-07 EP EP99904742A patent/EP1045840A1/en not_active Withdrawn
- 1999-01-07 CA CA002317651A patent/CA2317651A1/en not_active Abandoned
- 1999-01-07 NZ NZ505453A patent/NZ505453A/xx unknown
- 1999-01-07 PL PL99341672A patent/PL341672A1/xx not_active Application Discontinuation
- 1999-01-07 MA MA25421A patent/MA26595A1/fr unknown
- 1999-01-07 BR BR9906799-4A patent/BR9906799A/pt not_active IP Right Cessation
- 1999-01-07 WO PCT/EP1999/000021 patent/WO1999035135A1/en not_active Ceased
- 1999-01-07 EA EA200000623A patent/EA200000623A1/ru unknown
- 1999-01-07 KR KR1020007007581A patent/KR20010033988A/ko not_active Withdrawn
- 1999-01-07 AU AU25155/99A patent/AU2515599A/en not_active Abandoned
- 1999-01-07 IL IL13704099A patent/IL137040A0/xx unknown
- 1999-01-07 JP JP2000527536A patent/JP2002500220A/ja active Pending
- 1999-01-07 CN CN998036447A patent/CN1292785A/zh active Pending
- 1999-01-07 TR TR2000/01816T patent/TR200001816T2/xx unknown
- 1999-01-07 HR HR20000468A patent/HRP20000468A2/hr not_active Application Discontinuation
- 1999-01-07 SK SK1024-2000A patent/SK10242000A3/sk unknown
- 1999-01-07 AP APAP/P/2000/001860A patent/AP2000001860A0/en unknown
- 1999-01-08 CO CO99001036A patent/CO4820391A1/es unknown
-
2000
- 2000-06-27 IS IS5551A patent/IS5551A/is unknown
- 2000-07-07 NO NO20003514A patent/NO20003514L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1045840A1 (en) | 2000-10-25 |
| SK10242000A3 (sk) | 2001-02-12 |
| EA200000623A1 (ru) | 2001-04-23 |
| PE20000179A1 (es) | 2000-03-16 |
| NO20003514L (no) | 2000-09-07 |
| HUP0201343A2 (hu) | 2003-06-28 |
| PL341672A1 (en) | 2001-04-23 |
| NO20003514D0 (no) | 2000-07-07 |
| HUP0201343A3 (en) | 2003-08-28 |
| US6465451B1 (en) | 2002-10-15 |
| GB9800428D0 (en) | 1998-03-04 |
| CA2317651A1 (en) | 1999-07-15 |
| CN1292785A (zh) | 2001-04-25 |
| WO1999035135A1 (en) | 1999-07-15 |
| CO4820391A1 (es) | 1999-07-28 |
| AR014261A1 (es) | 2001-02-07 |
| IL137040A0 (en) | 2001-06-14 |
| ID25495A (id) | 2000-10-05 |
| KR20010033988A (ko) | 2001-04-25 |
| NZ505453A (en) | 2002-11-26 |
| AU2515599A (en) | 1999-07-26 |
| AP2000001860A0 (en) | 2000-09-30 |
| TR200001816T2 (tr) | 2000-11-21 |
| IS5551A (is) | 2000-06-27 |
| HRP20000468A2 (en) | 2000-10-31 |
| JP2002500220A (ja) | 2002-01-08 |
| MA26595A1 (fr) | 2004-12-20 |
| ZA9981B (en) | 2000-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9906799A (pt) | Composto, processo de tratamento de uma condição hiperlipidêmica em um mamìfero, composição farmacêutica, e, processo para a preparação de um composto | |
| BR9509683A (pt) | Compostos e processos para tratar uma condição clínica em um mamífero para tratar uma condição hiperlipidêmica em um manífero e para a preparação de um composto | |
| BR0212455A (pt) | Composto, formulação farmacêutica, combinação, uso de um composto, método para a profilaxia ou tratamento de uma condição clìnica em um mamìfero, e, processo para preparar um composto | |
| BR0214142A (pt) | Derivados e intermediários de n-adamantilmetila como composições farmacêuticas e processos para sua preparação | |
| YU56995A (sh) | Soli derivata indola | |
| BRPI0211665B8 (pt) | "composto de pirrol substituído" | |
| DK0626952T3 (da) | Hypolipidæmiske benzothiazepinforbindelser | |
| BR0108600A (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, métodos para tratamento de uma doença mediada por quimiocina e para tratamento de uma doença inflamatória | |
| BR0207694A (pt) | Composto ou um sal, solvato ou derivado fisiologicamente funcional deste, método para a profilaxia ou tratamento de uma condição clìnica em um mamìfero, formulação farmacêutica, combinação, uso de um composto ou de um sal, solvato ou derivado fisiologicamente funcional deste farmaceuticamente aceitáveis, processo para a preparação de um composto ou de um sal, solvato ou derivado fisiologicamente funcional deste, e, intermediários | |
| BR9914696A (pt) | Composto, processo para tratamento de distúrbio mediado por ciclo-oxigenase-2 em um indivìduo, e, composição farmacêutica | |
| BR9911488A (pt) | Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou de profilaxia de doenças inflamatórias, e para a preparação de um composto | |
| MX11031A (es) | Proceso para la preparacion de nuevas 1-fenil-3-naftaleniloxipropanaminas producto obtenido y composicion farmaceutica que lo incluye. | |
| YU60701A (sh) | Nova triciklička jedinjenja i njihova upotreba u medicini; postupak za njihovo pripremanje i farmaceutske kompozicije koje ih sadrže | |
| BR0212008A (pt) | Uso de um composto ou de um sal, solvato ou pró-medicamento deste, composição farmacêutica, composto ou um sal, solvato ou pró-medicamento deste, e, processo para a preparação deste | |
| BR0114323A (pt) | Composto ou um seu sal ou solvato farmaceuticamente aceitável, composição farmacêutica, uso do composto ou de um seu sal ou solvato farmaceuticamente aceitável, método de tratamento ou profilaxia de doenças inflamatórias, e, processo para preparar o composto | |
| BR0213350A (pt) | Derivados benzoxazina e benzotiazina e composições farmacêuticas contendo os mesmos | |
| BR0108024A (pt) | Composto, processo para a preparação de um composto, composição farmacêutica, uso do composto, método para o tratamento e/ou a profilaxia da hiperglicemia, hiperlipidemia, hipertensão, doença cardiovascular e determinadas desordens da alimentação, novo intermediário, processo para a preparação de um novo intermediário | |
| YU33401A (sh) | 13-točlani azalidi i njihova primena kao antibiotičkih sredstava | |
| BR0109617A (pt) | Composição farmacêutica, oligossacarìdeo, processo de preparação de oligossacarìdeos, e, utilização de oligossacarìdeos | |
| SE9103776D0 (sv) | New compounds | |
| BR9610175A (pt) | Composto processo de preparação do composto composição farmacêutica e utilização do composto | |
| BR0009281A (pt) | Derivados de morfolina, processo de preparação dos mesmos e composições farmacêuticas que os contêm | |
| BR0107282A (pt) | Composto, composição farmacêutica e métodos para prevenir ou tratar uma condição em um mamìfero e para inibir a coagulação de amostras biológicas | |
| ZA903111B (en) | 2-hydroxy-3-phenoxypropylamino compounds and pharmaceutical compositions containing them | |
| BR9913601A (pt) | Composto, uso do mesmo, composição farmacêutica, e, processo para a preparação de compostos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A,7A E 8A ANUIDADES |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1910 DE 14/08/2007. |